Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...